Breast Cancer

Breast cancer survivors find healing in the challenges of the road.

A brief from this year's San Antonio Breast Cancer Symposium discussing what new agents researchers have been testing when treating HER2-positive breast cancer.

A discussion about the best schedule for a class of drugs continues at the San Antonio Breast Cancer Symposium.

CURE Editor-at-Large, Kathy LaTour, tells the story of metastatic cancer survivor Brenda Hutchinson and her involvment with the HER2 Support Group

A brief from this year's San Antonio Breast Cancer Symposium where research was presented on the benefits that the drug Doxil can provide women who have relapsed after anthracycline treatment.

A brief from this year's San Antonio Breast Cancer Symposium discusses new research from eight clinical trials that studied whether or not certain factors help to predict response to neoadjuvant therapy prior to surgery.

A brief from this year's San Antonio Breast Cancer Symposium discussing new data showing that patients who receive radiation after having a mastectomy have a lesser chance of recurrence in certain early-stage cancers.

Advocate Joan Venticinque blogs about patient advocacy.

CURE publisher Susan McClure blogs from a survivor's perspective.

How a better understanding of cancer metastasis is suggesting better treatment approaches.

Why one family is committed to educating the public about male breast cancer.

A brief from this year's San Antonio Breast Cancer Symposium discussing IBIS-1, a trial that examines tamoxifen's effectiveness as a breast cancer prevention drug, and how breast density is effected by Tamoxifen.

A brief summarizing significant news from this year's San Antonio Breast Cancer Symposium regarding the TransATAC study's results showing that Oncotype DX may now be available for use in women who have taken aromatase inhibitors.

A brief from this year's San Antonio Breast Cancer Symposium detailing research from the AZURE trial that indicates adding the drug Zometa to chemotherapy before surgery may help to shrink breast tumors by an additional third.

Advocate Joan Venticinque blogs about patient advocacy.

CURE publisher Susan McClure blogs from a survivor's perspective.

CURE Editor-in-Chief Debu Tripathy, MD, blogs on medical issues from SABCS.

A combination of two well known breast cancer drugs could prove very successful when treating hormone receptor-positive, HER2-positive metastatic disease.

A look at how two-time breast cancer survivor Joan Venticinque got her start in advocacy and where she thinks the future may take her.

A brief discussing findings from this year's San Antonio Breast Cancer Symposium showing that research suggests that the drug Zometa may provide patients with reduced bone loss and a lesser chance of recurrence.

A brief discussing investigation agent RAD001 (everolimus), a drug currently approved to treat kidney cancer, and the findings that now show the drug may be used to treat breast cancer.

A brief discussing the data from the NOAH trial in which Herceptin was added to chemotherapy before surgery for HER2-positive locally advanced breast cancer.

CURE Editor-in-Chief Debu Tripathy, MD, blogs on medical issues from SABCS.

CURE publisher Susan McClure blogs from a survivor's perspective.